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Abstract
Emergency contraception (ec) can prevent pregnancy after sex, but only if taken
within 72 hours of intercourse. Over the past 15 years, access to ec has been ex-
panded at both the state and federal level. This paper studies the impact of those
policies. We find that expanded access to ec has had no statistically significant
effect on birth or abortion rates. Expansions of access, however, have changed the
venue in which the drug is obtained, shifting its provision from hospital emergency
departments to pharmacies. We find evidence that this shift may have led to a
decrease in reports of sexual assault.
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1 Introduction
In the 1960s, the introduction of oral contraception had a profound impact on women’s
fertility, education, and labor market outcomes (Goldin and Katz, 2002; Bailey, 2006).
Oral contraception, however, requires that women obtain a prescription and consume pills
on a daily basis in order to prevent pregnancy. This paper studies the impact of increasing
access to a different form of contraception, emergency contraception (ec), more commonly
known as the “morning-after pill.” ec, unlike oral contraception, is effective when taken
within 72 hours following intercourse. While ec cannot be used on a daily basis, it offers
women a chance to avert pregnancy after intercourse, when previously their only options
would have been either abortion or carrying the pregnancy to term.
Access to ec has changed dramatically in the last 15 years. Early forms of ec were
pioneered in the 1970s, but their existence was not widely known.1 It was not until 1997
that the Food and Drug Administration (fda) first approved a commercial ec product
in the United States, Preven, available by prescription only. In 1999, “Plan B,” the most
widely known form of ec, was introduced, and was also only available with a prescription.
At the time of ec’s introduction, researchers and policy-makers alike were optimistic about
its potential to prevent unintended pregnancies and abortion (Trussell et al., 2004). A 2002
Guttmacher Institute report estimated that ec had been responsible for a“substantial
proportion” of the decline in abortion rates over the last decade, estimating that ec had
averted 51,000 abortions in 2000 alone (Jones et al., 2002). This technology was expected
to be especially instrumental in preventing pregnancy from sexual assault; Trussell and
Stewart (2000) estimate that provision of ec following assault could have prevented 22,000
of the 25,000 pregnancies resulting from reported assaults in 1998.
To be effective, ec must be taken soon after intercourse. Because of this, various
1Ellertson (1996) summarizes the early history of ec. Initially, ec was simply an off-label use of
traditional oral contraceptives and intra-uterine devices.
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policies have been put in place since 1997 to increase access to ec. Between 1997 and
2007, 9 states allowed pharmacists to directly dispense ec without a prescription and
regardless of the patient’s age.2 We call such laws “pharmacy-access laws.” Furthermore,
16 states, plus the District of Columbia, mandated that hospitals inform victims of sexual
assault about ec.3 We call such laws “ed-access laws.” Finally, in 2006, the fda allowed
ec to be sold in pharmacies without a prescription to all women over the age of 18.4
This paper studies these expansions of access to ec. We study how such policies af-
fected fertility and abortion rates. We also explore how the expansion of access to ec
changed the venue in which women procure the medication, and the potential conse-
quences of such a change.
Despite the convictions of many policy makers, the theoretical impact of ec on fertility
and abortions is not obvious. We first present a simple model that explains the conditions
under which easier access to ec will lower natality and abortions. The effect of ec is
ambiguous, because easier access to ec, which mitigates a risk of sexual activity, may
change women’s behavior.
This paper then explores the impact that each of these policies has had on fertility-
related outcomes. We first estimate the impact of state policies before the 2006 fda
policy change. We then estimate the impact of the fda policy change by comparing
outcomes in states that previously had ec-related legislation to those that did not. We
find that pharmacy-access laws and ed-access laws had little effect on birth or abortion
rates. The estimates, for instance, rule out decreases in overall fertility larger than 2
percent. We find similar results even amongst sub-populations that are less likely to use
2Most of these states required that the pharmacist enter a collaborative practice agreement with a
physician, the others simply established a protocol. In the appendix, we distinguish between the two
types of laws as a robustness check.
3The majority of these laws mandate that the hospital itself provide the medication. Two states, South
Carolina and Ohio, passed ec-related legislation for assault victims, but failed to enforce it. We ignore
this legislation in our empirical specifications, following the classification of the Guttmacher Insitute.
4In 2009, this availability was extended to all women older than age 17. Our data do not allow us to
study this, more recent, policy change.
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regular contraceptives. Nonetheless, we demonstrate that sales of ec rose dramatically
during this time period. This suggests that women who purchased ec following the policy
change may have faced a small risk of pregnancy beforehand or that a behavioral response
counteracted the increase in contraceptive power.
Our results stand in stark contrast to research on other forms of contraception. Bailey
(2010) finds that greater availability of the contraceptive pill decreased marital fertility,
while Kearney and Levine (2009) demonstrate that the price of oral contraceptives affects
the teenage birth rate.5 Similarly, policies that have expanded access to abortion have
had a significant impact on fertility and the composition of births (Ananat et al., 2009,
2007; Donohue and Levitt, 2001), while policies that mandate waiting periods for abortion
may have decreased the abortion rate (Joyce and Kaestner, 2000).
Our results suggest more modest impacts of ec than two other existing studies that
focus on increased access to ec in the general us population.6 Oza (2009) studies the
change in outcomes after the fda policy change. She relies on a database of private
insurance claims and finds that the fda policy change decreased the number of abortions.
Zuppann (2010) studies how pharmacy-access laws affected birth rates before the fda
policy change. He finds that the state laws led to large decreases in birth rates.7
Our results, however, confirm findings from small-scale, randomized-controlled medical
trials. Glasier and Baird (1998) offer one group of women a supply of ec to keep at
home and require a second group to obtain ec through standard channels, only with a
prescription. The authors find that the first group had fewer unintended pregnancies.
The study, however, included only a small sample of subjects, selected because they had
all previously used ec or had an abortion. In contrast, other studies find no effect of
5In addition, there exists some evidence that oral contraceptives changed the composition of births
(Ananat and Hungerman, 2011).
6Another study by Durrance (2007) focuses on Washington state only, the first state to implement
pharmacy access.
7To our knowledge, no other study has estimated the impact of ed-access laws so far.
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ec on fertility (Raymond et al., 2006; Raine et al., 2005). Raymond et al. (2007) review
23 studies of ec and conclude that randomized access to ec has not been shown to
decrease unintended pregnancies. Glasier et al. (2004) find that the provision of emergency
contraception does not change abortion rates either.8
Having found little evidence that easier access to ec has changed fertility-related
outcomes, we then measure whether ec-related laws affect the venue in which women
acquire the pill. To do so, we rely on a near census of ed visits for selected states. We
find that the fda ruling led to a large decrease in ed visits related to ec. This suggests
that expansions of access to ec have affected the venue in which women acquire the
medication and thereby lowered the total cost of distributing ec. We also find that, in
the absence of pharmacy access laws, ed-access laws increase ec-related visits, indicating
that guaranteed access to ec may play a role in determining whether women go to the
ed.
While cost-saving, the shift to over-the-counter provision of ec may have led to un-
intended consequences. Sexual assaults may be one reason women seek ec at the ed.
Hospital staff, unlike pharmacists, provide other services beyond ec provision, and such
services may not be utilized if ec is accessed over-the-counter. In particular, we find sug-
gestive evidence that expansions of access to ec led to a decrease in the number of sexual
assaults reported to law enforcement. Such results must be interpreted cautiously; we rely
on only one source of data on sexual assaults and find an impact only of pharmacy-access
laws before the fda ruling. Still, this finding is consistent with the fact that assault
victims are likely to encounter less encouragement and opportunity to report the crime
8A related question is whether access to ec may encourage risky behavior. Previous research has
found little evidence for this. Raine et al. (2000) find that women given an at-home supply of emergency
contraception shifted to less effective methods of contraception. This result, however, has not been found
by other, similarly conducted studies (Jackson et al., 2003). Gold et al. (2004) find no effect of ec on
the use of other contraceptives. Meanwhile, Belzer et al. (2005) suggest that teenagers who are given
advanced provision of ec are more likely to have unprotected sex, but the methodology involved has been
criticized (Trussell et al., 2006).
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at a pharmacy than at an ed.
The paper proceeds as follows. Section 2 presents a theoretical framework that clarifies
how access to ec ought to affect outcomes. Section 3 describes the data at our disposal
and our empirical strategy. Section 4 then presents our empirical results; how access to
ec affects births, abortions, ed visits, and reports of sexual assault. Section 5 concludes.
2 Theoretical Framework
This section explains how ec can affect fertility-related outcomes. ec is unlike traditional
contraception in that it is intended for use after intercourse. Unlike abortion, however,
ec must be taken before one knows whether intercourse has resulted in pregnancy. In
this sense, ec lies between traditional contraception and abortion in a woman’s decision
tree. This section studies that decision tree with a simple model, inspired by the work of
Levine and Staiger (2002) and Kane and Staiger (1996).
The model predicts how ec will affect the number of sexual encounters, pregnancies,
abortions, and births. In general, the model suggests that the effect of ec on these out-
comes is surprisingly ambiguous. The ambiguity stems from how ec can change exposure
to pregnancy risk. Suppose, for instance, that women react to the introduction of ec by
having more sexual encounters. That reaction alone increases the number of births, while
the use of ec decreases the number of births. The net effect of ec on births and other
outcomes is thus ambiguous. Below, we present this intuition more formally.
2.1 Structure of the Model
Suppose that women face a utility gain from intercourse, S ∈ (0, S¯), and a utility gain
from having a child, B ∈ [B, B¯]. If B > 0, then a pregnancy is wanted, and if B < 0,
then a pregnancy is unwanted. These variables are randomly distributed in the population
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based on a density function g (s, b). Abortion is available once a woman is pregnant at a
utility cost, A.9
Once pregnant, women compare the benefits of carrying the pregnancy to term to the
cost of obtaining an abortion. They will choose abortion if B < −A. Thus, if a pregnancy
occurs, a woman will receive a utility of P ≡ max {B,−A}.
Suppose that, initially, the probability that a sexual encounter leads to pregnancy is
q. Therefore, a woman will consent to sex if S + q ·P > 0. The share of women who have
sex is:
γ (q) ≡
∫ B¯
0
∫ S¯
0
g(S,B)dSdB
+
∫ −A
B
∫ S¯
q·A
g(S,B)dSdB +
∫ 0
−A
∫ S¯
−q·B
g(S,B)dSdB. (1)
That is, the share of women who have sex is composed of those who want a baby (the
first term in equation 1) and those who do not. The latter are composed of two groups:
those who will pursue an abortion if pregnant (the second term in equation 1) and those
who will not (the third term in equation 1). A woman can only become pregnant if she
consents to sex, and thus the share of women who become pregnant is γ(q) · q.
2.2 The Effect of Emergency Contraception
Suppose that ec is introduced, and that it lowers the probability of pregnancy from q to
q′ at a cost of c. The parameter q′ reflects not just the effectiveness of the technology, but
also the probability that a woman obtains ec and uses it correctly.
After sexual intercourse, a woman must compare the benefits of taking ec with its
cost. She will prefer taking ec if S + q · P < S + q′ · P − c.10 Under these assumptions,
9These costs and benefits reflect not only the financial cost of abortion or pregnancy, but also stigma,
opportunity cost, and psychic costs.
10We assume that ec is less costly than abortion, and thus −A < cq′−q .
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ec will unambiguously raise the share of women who have sex, since some women with a
previously negative total payoff to sex now face a positive payoff.11
The share of women who become pregnant, however, may rise or fall after the introduc-
tion of ec. Wanted pregnancies are unaffected by ec, because women for whom a baby is
welfare-enhancing will not consume ec. Unwanted pregnancies, however, may increase or
decrease. That ambiguity stems from two forces. On the one hand, the availability of ec
leads more women to have sexual intercourse. On the other hand, pregnancy is now less
likely to occur. The appendix demonstrates that unwanted pregnancies will decrease if
the ability of ec to reduce pregnancies is large relative to the induced behavioral change.
The share of women who have an abortion may also rise or fall. There are two sources
of uncertainty that cause individuals to use abortion (Levine and Staiger, 2002). First,
some women decide to have sex based on a sufficiently high expected value of B, but are
uncertain of the true value of B until a pregnancy occurs. Such women are unlikely to use
ec to replace abortion, because they do not gain additional information about B from
waiting until after intercourse. The second source of uncertainty is the stochastic nature
of pregnancy itself. Abortion is a cost that is only realized if pregnancy occurs, whereas
traditional contraception and ec must be used before knowing whether pregnancy will
occur. No additional information is gained by waiting until intercourse occurs, but ec
may act as insurance against pregnancy. The net effect of ec on abortion is ambiguous,
and for the same reason that the effect of ec on pregnancies is ambiguous. On the one
hand, ec induces more women to choose sexual intercourse. On the other hand, the
probability that these women need an abortion falls, because they consume ec. Finally,
combining the ambiguous effect of ec on pregnancies and abortions yields the prediction
that ec may raise or lower the number of births.
The ambiguity of ec on these outcomes depends on the magnitude of q′ relative
11The appendix presents a formal proof of both this prediction and the following predictions.
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to q. If, for instance, ec were to reduce the probability of pregnancy from q to zero,
then ec would unambiguously reduce the number of pregnancies, abortions, and births.
ec, however, only reduces the probability of pregnancy by 75–95 percent (Trussell and
Raymond, 2012). Over one year, a sexually active woman who uses ec as her only form
of birth control faces a 20–40 percent risk of pregnancy. Consequently, we cannot rule out
that the effect of ec on these outcomes is theoretically ambiguous.12
In this way, the model describes the introduction of ec and not expansions of access
to ec. The model, however, leads to nearly identical predictions in either case. We clarify
the difference between the introduction of ec and expansions of access in the theoretical
appendix.
2.3 Emergency Contraception versus Traditional Contraception
This model does not explicitly capture the choice between traditional contraception and
ec. Formally incorporating traditional contraception into the model would complicate the
derivations, but would not provide additional insights.13 Instead, we discuss traditional
contraception informally as follows.
Traditional contraception must be purchased before sexual intercourse. Women who
are certain of the benefits of sex, S, will purchase traditional contraception rather than
ec.14 For such women, ec provides no additional benefit. There also exist, however,
women for whom the benefits of sex, S, are uncertain. For such women, ec offers an
advantage over traditional contraception. When the benefits of sex, S, are uncertain but
expected to be low, women may not wish to purchase traditional contraception. If S is
revealed to be very large, then such women can purchase ec after intercourse. Uncertainty
12Note that the introduction of ec unambiguously increases the welfare of women in this framework.
13Women would have to choose between traditional contraception and ec based on which one provided
the highest protection at the lowest cost. If ec were relatively more expensive, no woman would use
it and an expansion of access to ec would have no effect on outcomes. If, on the other hand, ec were
relatively inexpensive, then some women would consume ec. Only in this case would ec affect outcomes.
14ec is comparable in cost to one month of oral contraceptives.
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in S, or rather, uncertainty over future sexual encounters, thus drives demand for ec.
A second reason women may choose ec involves stochastic shocks to q. For example, if
a condom breaks during intercourse, then the probability of pregnancy is suddenly higher
than it had been before. The woman may then consume ec, as a result. In this way, ec
can be used once additional information about S and q is revealed.15
Without such uncertainty, very few economic agents would consume ec. First, ec is
relatively expensive. Second, ec cannot be used frequently, and provides little additional
benefit if a primary method of contraception is already used properly. In this sense,
the availability of ec will only affect women who face greater uncertainty over future
sexual encounters. Women who face such uncertainty are more likely to be young, poorer
and unmarried. For that reason, we stratify some of the empirical results below on age,
minority, and marital status.
2.4 Victims of Sexual Assault
ec may also be used in cases of sexual assault. In the context of the model, such women
are those for whom S + q · P is negative, and yet they are forced to have sex. For such
women, ec does not induce a behavioral response; the rate of sexual assaults is likely
unaffected by the availability of ec.16 Thus, in contrast to the ambiguous results above,
ec has an unambiguous effect on victims of sexual assault. For victims of sexual assault,
the availability of ec reduces the number of births and abortions.17 We are aware of no
studies that assess the effect of contraception access on victims of sexual assault. We
believe that this represents a fruitful avenue for future research.
15Abortion is available once q has been realized and potentially, once additional information regarding
B has been revealed.
16Furthermore, given the low probability of assault, women are unlikely to insure against assault by
using traditional contraceptives and thus face a high q if they are not using contraceptives for another
reason.
17Victims of assault, however, compose a small share of the total population. It is thus difficult to
estimate the effect of ec on outcomes for that population alone.
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We will also test empirically how the availability of ec affects the reporting of sexual
assaults. When a sexual assault is reported to law enforcement, the victim provides a
public good while bearing a private cost. She provides authorities with the identity of the
perpetrator and thus lowers the probability that the perpetrator commits another assault.
As in the case of other public goods, reporting of assaults may be under-provided.18 We
present below suggestive evidence that access to ec in pharmacies reduces the share of
assaults that are reported to law enforcement. This suggests that when the private benefit
to reporting is diminished, fewer assaults are reported. In that sense, wider access to ec
decreases the private costs borne by victims, but may also decrease the provision of a
public good. We discuss this implication further below.
3 Data and Empirical Strategy
We measure the effect of ec with a simple, difference-in-difference framework. Specifically,
we first evaluate the state laws that expanded access, and then test how states that passed
such laws were differentially affected by the fda policy change.
Table 1 presents the dates when ec-related laws were passed.19 Between 1997 and
2006, 9 states passed pharmacy-access laws and 10 states passed ed-access laws. An
additional 6 states, and the District of Columbia, passed ed-access laws after the fda
policy change made ec available at pharmacies.20 The states that passed ec-related
legislation may be systematically different from states that did not. Still, all of our
empirical results control for fixed differences between the states. Moreover, we test for
time-varying differences between states by including linear time trends in our regressions
18After an assault, the victim may also be tested for sexually-transmitted infections. This may involve
an additional positive externality.
19For the results below, we adjust the relevant date that each law was passed based on the outcome.
For visits to the ed, we use the actual date. For abortions, we add 60 days to the law’s passage, to
account for the average gestation at abortion. For births, we add 266 days.
20Note that both types of state laws did not restrict the age at which women could obtain ec, whereas
the fda ruling made ec available only to women older than 18.
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and by exploring event-study specifications.21
The fda policy change was announced on August 24, 2006. However, unlike the state
laws, the fda policy required suppliers to produce a new, over-the-counter version of
ec. Suppliers shipped that version in November of 2006, roughly three months after the
fda policy change. We thus consider the effective date of the fda policy change to be
November of 2006.
For the state laws, we estimate a regression of the form:
yst = β · I {EC State Lawst}+ γ ·Xst + αs + αt + αs · t+ εst,
where yst is an outcome in state s at time t and I {EC State Lawst} is equal to 1 when
the state has such a law in place.22 The regression allows each outcome to evolve along a
separate linear time-trend and to differ permanently by state. We also include a variety
of time-varying controls in each regression: the state unemployment rate, its poverty rate,
welfare benefits for a family of four, the afdc/tanf benefit level, and the availability of
subsidized contraception through Medicare as compiled by Kearney and Levine (2009).23
We adjust the standard errors to allow for auto-correlation between observations from
the same state.24 This framework requires one key assumption: that, in the absence of
the policy changes, the path of the outcomes in each state would have differed only by a
linear trend. We test the validity of that assumption below using more flexible event-study
specifications.
21A table without state-specific time trends is included in the appendix.
22For annual data, we code a law as having been implemented if the law (or its expected consequence)
was in place for more than 183 days of the year. For monthly data, we require that the law or its
consequences be in place for more than 14 days of the month.
23The information on welfare comes from the University of Kentucky Poverty Research Center database
(2011) and from Bitler et al. (2006).
24For these regressions, we restrict our sample to the years before the fda policy change, since we expect
that states with such laws in place would be affected very differently by the fda ruling. Specifically,
for outcomes in which we expect an immediate change in behavior, we only look at years before (and
including) 2005, while for births, where we expect the outcome to be delayed by a year, we only restrict
our sample to years before (and including) 2006.
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To evaluate the 2006 fda policy change, we estimate a similar regression in which
states that had already passed a pharmacy-access law are the control group. We only use
the latest period of the data (2004–2008) for that estimation since many of the control
states changed their laws during the previous period.25 Although the fda policy was not
a substitute for ed-access laws, it may have obviated such laws; thus, we also compare
the impact of the fda policy on states that previously had ed-access laws in place.
We have compiled outcomes from a variety of sources. We observe the number of
births per month in each state from a census of births collected by the National Vital
Statistics System.26 For abortion rates, we rely on state-by-year estimates of the number
of abortions calculated by the Centers for Disease Control and Prevention.27. We have
also compiled data on sexual assaults reported to authorities via the Federal Bureau of
Investigation (fbi) Uniform Crime Report.28
Finally, we have compiled a large database of ed visits by month and year based on
data from the Healthcare Cost and Utilization Project (hcup). Our sample includes a
near census of ed visits from Arizona (2005–2008), California (2005–2008), Iowa (2004–
2007), New Jersey (2005-2008), and Wisconsin (2004–2008).29 Of these five states, New
Jersey, Wisconsin, and California passed ed-access laws.30 We construct aggregate counts
of all ed visits by month for these states, and isolate ed visits in which the patient received
25In such regressions, we exclude any state that changed its policies such that it would have affected
the outcomes of interest in 2006.
26We stratify births by the age of the mother. We have also stratified births based on the marital
status and race of the mother. The results are extremely similar to the ones presented below.
27These abortion data rely on states themselves reporting the relevant statistics, unlike the survey data
compiled by the Alan Guttmacher Institute. The latter, however, are not available on an annual basis
by state. We have data on 48 states in our sample.
28The crime data exist at the state-year level. Some states make available monthly crime data, but too
little such data exist to precisely estimate the regression above at the monthly level.
29The administrative data cover all hospitals regulated by the state. Thus, for instance, we do not
observe ed visits at Veteran Administration hospitals. Such visits are likely a very small share of all
visits related to ec.
30California also passed a pharmacy-access law. Both California laws were implemented before the
hcup sample period, which prevents us from measuring their impact.
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ec or in which the patient was listed as a sexual assault victim.31
4 Results
This section presents our empirical results. We first discuss the effect of access to ec on
births and abortions, outcomes on which most of the public debate and previous literature
has focused. As our model indicates, however, the effect of ec on such outcomes is
theoretically ambiguous. We then describe how access to ec affects visits to hospitals
and reports of sexual assault, outcomes for which the model suggests we are more likely
to observe an impact.
4.1 Births and Abortions
Table 2 presents a series of difference-in-difference estimates that test for the effect of
access to ec on natality. The regressions include state-specific linear time trends and
time-varying control variables.32 We focus on four different measures of natality: total
births, total births for women under the age of 18, total births for women aged 18–30, and
total births for women older than 30. The first panel restricts the sample to 1995–2006,
before the fda policy change. The second panel presents estimates based on 2004–2008,
in which states with pharmacy-access laws compose the control group for the fda policy
change.33
Panel A of Table 2 suggests little relationship between natality and ed-access laws;
all point estimates are extremely small, although the confidence intervals only rule out
31ec-related visits have International Classification of Diseases 9th Revision (icd-9) code “V2503,” and
assault-related visits have icd-9 code “V715.”
32As described above, these time-varying control variables include the state unemployment rate, its
poverty rate, welfare benefits for a family of four, the afdc/tanf benefit level, and the availability of
subsidized contraception through Medicare as compiled by Kearney and Levine (2009).
33The table presents regressions that include controls for both types of state laws simultaneously. We
obtained similar results when evaluating each law separately.
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decreases in overall natality of roughly 2 percent.34 Additionally, Panel A presents no
evidence that pharmacy-access laws lowered births in each state. In contrast, the re-
sults suggest a 2.2 percent increase in births after states pass a pharmacy-access law (for
women aged 18–30). That increase in births is surprisingly statistically significant. To
test whether this increase is a true effect of the legislation, we run event-study regres-
sions, which estimate the effect of pharmacy-access laws in each year before and after
their passage. Figure 1 presents the results of that regression. The figure suggests that
pharmacy-access laws did not have a discontinuous effect on natality. Natality in states
that passed pharmacy-access laws was on an increasing (non-linear) trend before passage
of the laws. This suggests that the results in panel A of Table 2 are misleading.35
Furthermore, if the results of panel A were taken at face value, they would imply an
unusual response to pharmacy-access laws. As described by our model, access to ec will
increase the birth rate when the behavioral response to the drug is substantially larger
than the birth-prevention effect of the drug. The point estimates seem unusually large
given that less than 5 percent of women say that they have used ec in the last year.
Those women who have used ec used it less than twice on average (Zuppann, 2010). Any
increase in births would need to be driven by women changing their behavior based on
availability of the drug, but becoming pregnant nonetheless.
Finally, the bottom panel of Table 2 suggests little effect of the fda policy change on
natality. For 18–30 year-olds, states with no pharmacy-access law experienced a statisti-
cally insignificant 1.8 percent decrease in natality after ec was available over-the-counter.
Such estimates can reject a negative impact of the fda policy change on births larger
34The regressions in Table 2 are demanding of the data; they include many controls. We find, however,
qualitatively similar estimates when we exclude state-specific linear time trends and state-specific time-
varying control variables. Such results are presented in Appendix Table 1.
35The results of Table 2 do not match the findings of Zuppann (2010). Our approach differs from that
of Zuppann (2010) in several ways. We analyze natality at the monthly level in log form, whereas he
focuses on annual birth rates. We also focus on a narrower range of years to study. Finally, we rely on a
slightly different set of dates for each pharmacy-access law.
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than 4 percent.
Potentially, we may not estimate a statistically significant effect here because the
utilization and impact of ec is too low in the general population. We have conducted the
analysis for many sub-populations (race, marital status, number of previous pregnancies,
and so on) and have still found no impact. For instance, Table 3 presents estimates of
our preferred specification solely for births by black, unmarried women.36 We focus on
this population, because it is the group least likely to be using traditional contraceptives,
and thus at highest risk of unintended pregnancy without access to ec. Table 3 presents
no evidence that natality fell for that population after the policies of interest.
Table 4 presents a similar set of estimates to Table 2, but with abortions by state and
year as the outcome of interest. As a whole, the table suggests no effect of ec-related
laws on abortion. No point estimates are statistically significant at conventional levels,
but the confidence intervals are wide. For instance, the results only rule out a reduction
in abortions among women aged 20–29 of more than 12 percent after ed-access laws. The
estimated impact of pharmacy-access laws is positive for most age groups, but statistically
insignificant. The results do not reject reductions of less than 7 percent.
In summary, neither Table 2 nor Table 4 present significant evidence that ec-related
legislation affected births or abortions.37 This confirms the results of medical studies, but
care should be taken in interpreting these results.
First, one may wonder whether the legislation had little effect because it did not
actually increase the consumption of ec. (This would be akin to a weak first stage in
an instrumental variable setting.) We investigate this possibility with sales records from
36Information on educational attainment exists only for certain states and certain years, thus the
number of observations falls across columns in Table 3.
37We also explored whether birth and abortion rates of 18- versus 17-year-olds changed differently
around the fda ruling, given the differential treatment of ages under the policy. To do so, we used
natality and abortion records from the state of Texas. We found no evidence of such a pattern. Moreover,
we used the natality records to explore whether there was any change in women’s attributes around the
fda ruling and were unable to obtain any significant results as well.
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Barr Pharmaceuticals, the primary producer of ec. Unfortunately, the sales data are
not available at the state-year level. Nevertheless, we directly observe the impact of the
fda policy change on national sales of ec. Figure 2 plots the total sales of Plan B from
2006 through 2009. The figure demonstrates the rapid decline of prescription sales for
ec following the August, 2006 fda policy change. The policy change also led to a rapid
increase in over-the-counter sales, as Barr Pharmaceuticals released the newly packaged
product for over-the-counter sale. From 2006 to 2007, Plan B sales more than doubled,
increasing by $47 million, with unit sales going from approximately 16,000 sales per week
to over 34,000 in 2007. Sales continued a steady climb, doubling again between 2007 and
2009. This large increase in Plan B sales is evidence of the direct effect of the fda policy
change. We are thus skeptical that the lack of a pattern in Table 2 and Table 4 is driven
by lack of variation in sales of the pill. Furthermore Kavanaugh et al. (2011) argue that
pharmacy-access of ec is responsible for doubling the number of women who have ever
used ec from 4 percent in 2002 to nearly 10 percent in 2008.
A second possibility is that we may simply be unable to detect significant effects of the
ec-related legislation because of the way ec operates. ec only prevents pregnancy from
a single sexual encounter, so it eliminates a risk of pregnancy of only 3–5 percent, the
risk of pregnancy from a single, unprotected sexual encounter. If, however, women use ec
because they believe themselves to be at a greater risk of pregnancy, then women taking
ec may face a 10 percent pregnancy risk, the approximate peak at pregnancy during the
menstrual cycle (Wilcox et al., 2001).38 In that case, if ec lowers this pregnancy risk by
75 percent, then women taking ec would experience a 7.5 percentage-point reduction in
pregnancy risk.39 If the fda policy change caused roughly one-million additional pills to
38The risk of pregnancy from a single, unprotected sexual encounter reaches 29 percent on the day
before ovulation, but due to ovulation occurring irregularly within the menstrual cycle, a woman is
unlikely to pinpoint this peak risk.
39Clinical trials show ec to be up to 89 percent effective, but this effectiveness decreases with the time
between intercourse and consumption of the pill.
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be consumed in its first year, then there would be 75,000 averted pregnancies, slightly less
than 2 percent of all births. The regressions above cannot rule out such a change.
Alternatively, women who take ec may be at a decreased risk of pregnancy. For
instance, women who take ec may do so principally because another method of contra-
ception has failed. Some studies indicate that this is indeed the case (Trussell et al.,
2004). If women who consume ec face a lower risk of pregnancy from a single sexual
encounter than average, say 2 percent, then one million additional pills would prevent
15,000 unintended pregnancies, a negligible amount relative to total births.
Under either scenario, very large changes to births or abortions are unlikely, given that
each additional pill prevents pregnancy from only a single sexual encounter. More broadly,
unexpected sexual encounters may account for a small percentage of overall pregnancies.
Roughly half of women seeking abortions had been using some form of contraception, and
few report unexpected sex as a factor in their abortion (Jones et al., 2002). If individuals
who use ec actually face a low risk of unintended pregnancy, and individuals most likely
to experience unintended pregnancy are unlikely to seek ec, then the impact of expanded
access will be greatly diminished. We conclude that policies offering over-the-counter
access to ec avert a private cost in acquiring the pill through a physician, but do not
avert the social cost of unintended pregnancy.
4.2 ED Visits
Despite the estimated null effect on birth and abortion rates above, state and federal
legislation may have changed the way women acquire ec. To test for that possibility,
Figure 3 presents monthly counts of ec-related visits to emergency departments. The
vertical line indicates the date when the fda allowed all women to obtain ec in pharmacies
without a prescription.40 The figure shows a clear decrease in ec-related visits after the
40We restrict the sample to visits by women older than age 18. Only such women would have been
affected by the legislative change. No drop is observed for ec-related visits by women younger than 18.
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fda ruling. ec-related visits decrease from roughly 250 each month to roughly 150 each
month. In contrast, the number of other visits seems to rise. Though a relatively small
share of ed visits are related to ec, Figure 3 suggests that such visits became less common
after women could obtain ec in pharmacies. Given that our five states capture about 20
percent of the population in the United States, this would suggest that the fda policy
change led to a decrease of about 500 visits per month to ed’s.
In contrast to the pharmacy-access policies, we would expect ed-access laws to increase
visits to the ed to obtain the pill, as its provision would be guaranteed. ed data do not
exist that would allow us to estimate how each ed-access law affected the number of ed
visits. Nevertheless, we have obtained records of ed visits for New Jersey, which passed
such a law in April of 2005. Figure 4 presents ed visits in New Jersey before and after
the state passed its ed-access law. The figure suggests that ec-related ed visits were
decreasing before the law was passed and then increased dramatically immediately after
the law was passed. In contrast, other ed visits experienced a secular increase before
and after the law. The magnitude of the change suggests an increase of about 25 visits
per month. Given that the population of New Jersey is about 3 percent of that of the
United States, that increase is slightly larger than the decrease that was experienced after
the fda ruling. By contrast, no such pattern is observed in Wisconsin, which passed its
ed-access law after the fda policy change. This implies women did not increase their
visits to the ed for ec in response to guaranteed access when a lower cost route, pharmacy
access, is already available.
As a whole, these figures suggest that expansions of access to ec substantially changed
the venue in which women procured the medication. Given the expense of ed visits
(Bamezai et al., 2005), the figures suggest that such laws affect the total cost of distribut-
ing ec. These costs are both monetary as well as related to the time and stress associated
with visiting the ed. However, patients in an ed are given access to a wider array of
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staff and services than customers in a pharmacy. Potentially, that difference may lead to
changes in outcomes. We test for such changes next.
4.3 Reports of Sexual Assault and EC
We next test whether expansions in access to ec affect reports of sexual assault. A priori,
one might expect such an effect. In our model, victims of sexual assault are those for
whom the impact of ec would be the largest. Furthermore, as demonstrated above, both
state pharmacy-access laws and the fda policy change enabled women to procure ec in
pharmacies rather than hospitals. In either a pharmacy or an emergency department, it
is the victim’s decision as to whether a sexual assault is reported to the police. Hospital
staff, however, may be more effective at encouraging women to report such crimes.
Table 5 presents the results of difference-in-difference regressions with reported sexual
assaults as the outcome of interest. The second row of Panel A suggests that pharmacy-
access laws did indeed reduce reported sexual assaults. In particular, states experienced
a significant 9 percent decrease in reported assaults after they passed pharmacy-access
laws. This implies a decrease of 0.31 reported assaults per 10,000 people (compared to an
average of 3.5 assaults per 10,000 people). While this effect is not large, it is consistent
with the decreased number of visits to the ed (6,000 annually).
To check that this result is not spurious, Figure 5 presents the point estimates from
an event-study specification that evaluates the effect of state ed-access laws on reports
of sexual assault. None of the 95-percent-level confidence intervals in Figure 5 exclude
zero. We find this unsurprising; an event-study specification is demanding, given that
these data only exist at the state-year level. Still, we find the figure suggestive. The
point estimates suggest that assaults dropped for all post-law periods and did so exactly
the year that the pharmacy-access laws were passed. While that drop is not statistically
significant at conventional levels, the point estimates do not form a linear trend, but
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rather a step function.
In addition, Table 5 suggests that ed-access laws increased the reporting of sexual
assaults. Perhaps such laws increased the number of women choosing to go to the ed
following a sexual assault. Those point estimates are only statistically significant at the
10–15 percent level. Nevertheless, the finding is consistent with the role that ed access
has in guaranteeing care for prevention of pregnancy to assault victims. This further
suggests that women who seek ec in hospitals are likely to report sexual assault.
Columns 3 and 4 of Table 5 report the results of a falsification check. We estimate
similar regressions in which the number of aggravated assaults reported to the fbi is the
dependent variable. Aggravated assaults are non-sexual in nature, and the reporting of
such crimes should not be related to the availability of ec. Reassuringly, columns 3 and
4 suggest that ec-related legislation had no effect on aggravated assault.41 Panel B of
Table 5 presents similar estimates for the fda policy change. We find no evidence of a
change in the report of sexual assaults after the national policy change.
Finally, we examine the impact of the fda policy change on the nature of ed visits.
Specifically, we test whether the fda policy change affected ed visits for sexual assaults in
our hcup sample. Figure 6 presents the number of such visits over time.42 The number
of sexual-assault-related visits fell dramatically around the time of the fda ruling. In
contrast, ed visits for other conditions remained on the same trend. Although visits for
sexual assault became more common in the summer of 2007, the relative number of such
visits remained below trend.43 The effect of the fda policy change is also clear, however,
if we control for month-of-year fixed effects. The magnitude of this change is substantial;
assault-related visits decreased by about 100 visits per month in our five-state sample.
Overall, this evidence is suggestive. It implies that pharmacy access to ec may have
41Reports of robbery are similarly unaffected.
42Only visits by women older than 18 are in the sample.
43Visits related to sexual assault are subject to a seasonal pattern, occurring more frequently in the
summer than in the winter.
20
led to a decrease in reported sexual assaults. The welfare implications of this finding are
unclear. Easier access to ec means lower transaction costs for victims of sexual assault.
However, it may also limit the other services provided to sexual assault victims, and
hinder the apprehension of perpetrators. More research is needed in this area, to confirm
how access affects assault reporting, and what policy steps could be taken to mitigate the
unintended consequences of increased access.
5 Conclusions
In summary, this paper studies the effects of access to ec. We first present a theoretical
framework that suggests that the net effect of ec is ambiguous. On the one hand, there
exists a direct effect—the consumption of ec prevents pregnancies. On the other hand,
there exists an indirect effect; ec may induce a behavioral response which leads to more
sexual encounters, and hence, more pregnancies. Finally, the likely impact of ec depends
on when additional information on uncertain variables is revealed to the woman: informa-
tion revealed near the time of intercourse (such as a broken condom) is related to ec use,
while information that is gained long before or long after intercourse will make ec less
useful relative to traditional contraception or abortion. Our model also suggests that the
use of ec relative to traditional contraceptives and abortion will depend on the timing of
information updates on the costs and benefits of unprotected sex and pregnancy.
Consistent with this model, we find no empirical evidence that expanded access to ec
has decreased birth rates or abortions, even for at-risk populations. We caution that the
associated confidence intervals are relatively wide, and that more research is needed to
recover precise estimates. Still, we do not observe large changes in natality or abortion, as
some opponents of ec have feared, nor do we find large decreases in unintended pregnancy,
as some proponents had hoped. We find that wider access to ec increases utilization of
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ec, thus we do not believe that a lack of variation in the actual consumption of ec is
driving our results. ec may mostly affect women for whom the chance of pregnancy is
low, and thus it would be impossible to observe very large decreases in response to such
policies.
These results clarify the dynamics of unintended pregnancies. The likely impact of ec
depends on when additional information on uncertain variables is revealed to the woman:
information revealed near the time of intercourse (such as a broken condom) encourages
ec use, while information that is gained long before or long after intercourse will make
ec less useful relative to traditional contraception or abortion. Our results imply that
few unintended pregnancies are anticipated immediately after intercourse, indicating that
uncertainty around the time of intercourse may not be a major driver of unintended
pregnancy. Long term decisions may play a larger role in determining risk for unintended
pregnancy, and the women facing the greatest risk of such pregnancies may not be the
users of ec. Sexual assault victims represent an exception, given that they face a large
unanticipated shock that ec can be used to mitigate.
Our results do suggest that expanded access to ec has changed the venue in which
women obtain ec, encouraging women to visit eds when access there is guaranteed, and
then switch from eds to pharmacies when the drug is available otc. Visits to pharmacies
are less expensive than visits to emergency departments. Thus, if nothing else, expansions
in access to ec have lowered the total cost of distributing the drug.
This lower cost, however, appears to have brought a potential unintended consequence:
access to ec in pharmacies may reduce the reporting of sexual assault. To mitigate this
impact, new policies may be necessary to encourage crime reporting by sexual assault
victims that visit pharmacies. Further evidence is needed on this, but such a possibility
was not, to our knowledge, discussed in the debate over ec, and deserves greater attention.
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A Appendix
Before ec, the share of women who have an unwanted pregnancy is:
q ·
(∫ −A
B
∫ S¯
q·A
g(S,B)dSdB +
∫ 0
−A
∫ S¯
−q·B
g(S,B)dSdB
)
.
The fraction of women who have an abortion before ec is introduced is:
q ·
∫ −A
B
∫ S¯
q·A
g(S,B)dSdB.
After ec is available, the model described in section 2 makes four predictions. First,
it predicts that the share of women who have sex will unambiguously rise. The share of
women who have sex after the introduction of ec is:
∫ −A
B
∫ S¯
c−q′·A
g(S,B)dSdB +
∫ c
q′−q
−A
∫ S¯
c−q′·B
g(S,B)dSdB
+
∫ 0
c
q′−q
∫ S¯
−q·B
g(S,B)dSdB +
∫ B¯
0
∫ S¯
0
g(S,B)dSdB.
This share is unambiguously larger than the share before ec, γ (q).
Note also that as c increases, the share of women having sex decreases, because the
derivative is given by:
−
∫ −A
B
g(c− q′ · A,B)dB −
∫ c
q′−q
−A
g(c− q′ ·B,B)dB
+
1
q′ − q
(∫ S¯
− cq
q′−q
g(S,
c
q′ − q )dS −
∫ S¯
− cq
q′−q
g(S,
c
q′ − q )dS
)
=
−
∫ −A
B
g(c− q′ · A,B)dB −
∫ c
q′−q
−A
g(c− q′ ·B,B)dB < 0.
Second, the model predicts that the share of women who become pregnant after ec
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may rise or fall. The share of women who become pregnant once ec is available is:
q ·
(∫ 0
c
q′−q
∫ S¯
−q·B
g(S,B)dSdB +
∫ B¯
0
∫ S¯
0
g(S,B)dSdB
)
+
q′ ·
(∫ −A
B
∫ S¯
c+q′·A
g(S,B)dSdB +
∫ c
q′−q
−A
∫ S¯
c−q′·B
g(S,B)dSdB
)
.
For this number to be lower than the number of pregnancies before ec, ec must lower the
number of unwanted pregnancies. (ec has no effect on the number of wanted pregnancies.)
The number of unwanted pregnancies will fall only if:
q′
q
<
∫ −A
B
∫ S¯
qA
g(S,B)dSdB +
∫ c
q′−q
−A
∫ S¯
−qB g(S,B)dSdB∫ −A
B
∫ S¯
c+q′A g(S,B)dSdB +
∫ c
q′−q
−A
∫ S¯
c−q′B g(S,B)dSdB
< 1,
that is, only if the effectiveness of ec surpasses the number of added sexual encounters it
generates.
When the price of ec rises, the impact on pregnancies is given by the following ex-
pression:
−q′ ·
(∫ −A
B
g(c+ q′ · A,B)dB +
∫ c
q′−q
−A
g(c− q′ ·B,B)dB
)
1
q′ − q ·
(
−q
∫ S¯
− cq
q′−q
g(S,
c
q′ − q )dS + q
′
∫ S¯
− cq
q′−q
g(S,
c
q′ − q )dS
)
=
−q′ ·
(∫ −A
B
g(c+ q′ · A,B)dB +
∫ c
q′−q
−A
g(c− q′ ·B,B)dB
)
+
∫ S¯
− cq
q′−q
g(S,
c
q′ − q )dS.
Third, the model predicts that the share of women who have an abortion may rise or
fall. The share of women who have an abortion after ec is introduced is:
q′ ·
∫ −A
B
∫ S¯
c+q′·A
g(S,B)dSdB.
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This number may be larger or smaller than the number of abortions without ec. Abortion
will only decrease if:
q′
q
<
∫ −A
B
∫ S¯
qA
g(S,B)dSdB∫ −A
B
∫ S¯
c+q′A g(S,B)dSdB
< 1.
For an increase in the price, the comparative statics are much simpler and indicate
that a lower price of ec will increase abortions since the derivative is given by:
−q′ ·
∫ −A
B
g(S, c+ q′ · A)dS < 0.
Expansions of access to ec will unambiguously increase the number of abortions as
long as abortions are more expensive than ec. On the one hand, the availability of ec
induces more women to have sex. Some of these women are those who would want an
abortion if ec fails. This mechanism thus raises the abortion rate. On the other hand,
abortion will only now be needed when ec fails, and thus the availability of ec reduces the
abortion rate. When the cost of ec (c) decreases, this second effect is not present. Based
on the assumptions of the model, all women who were previously pursuing abortion were
already consuming ec. Thus the only effect of a decrease in c is to increase the number
of women who use ec. And, because ec is not foolproof, for some women, ec will fail
and lead to more abortions. This result would not hold if, for some women, abortion
is actually cheaper than ec, in which case, the effect of lowering c would be ambiguous
again.
Finally, the model predicts that the number of births may rise or fall. Births will fall
if:
q′
q
<
∫ c
q′−q
−A
∫ S¯
−qB g(S,B)dSdB∫ c
q′−q
−A
∫ S¯
c−q′B g(S,B)dSdB
< 1
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An expansion of access will also have an uncertain impact since the derivative is given by:
−q′ ·
∫ c
q′−q
−A
g(c− q′ ·B,B)dB +
∫ S¯
− cq
q′−q
g(S,
c
q′ − q )dS
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Figure 6. Sexual Assaults Visits in HCUP Sample
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State or region Pharmacy-Access Law Pharmacy-Access Type ED-Access Law ED-Access Type
25-Apr-2002 Collaborative practice
9-Apr-2007 inform
1-Jan-2002 State-approved protocol* 1-Jan-2003 provide
15-Mar-2007 inform
1-Oct-2007 provide
24-Jun-2003 Collaborative practice
1-Jan-2002 inform
3-Mar-2004 State-approved protocol**
15-Sep-2005 Collaborative practice 14-Dec-2005 provide
1-Aug-2007 provide
15-Aug-2005 Collaborative practice
20-Apr-2005 provide
15-May-2003 State-approved protocol 1-Oct-2003 provide
31-Jan-2004 provide
31-Mar-2003 recommendation†
1-Jan-2008 provide
26-Jan-2008 provide*****
19-Jun-2005 pay (but not inform)†
1-Sep-2005 inform 
25-Mar-2009 provide
29-Mar-2006 Collaborative practice
1-Jul-1997 Collaborative practice*** 13-Jun-2002 provide
25-Mar-2009 provide
28-Mar-2008 provide
24-Aug-2006 18 and over only****
*
**
***
****
*****
†
Note: 
Sources:
These states are not considered "access" states by Guttmacher, and so we exclude in all specifications.
Dates denote effective date if available, legislation signing date if effective date unknown, and adoption by 
legislature date if signing date unknown.
National Conference of State Legislatures; state legislative records; Guttmacher Institute; Lexis Nexis and 
Google news search.
Table 1. State Laws
National
Legislation initially allowed collaborative practice only, but was expanded to state protocol 10/1/03.
Hybrid model: collaboration required but not regulated. Listed as state protocol by Guttmacher.
Initially, a two-year pilot program building on state's existing collaborative practice law for some drugs.
Expanded to 17-year-olds on April 22, 2009.
Includes conscience exemption.
Texas
Utah
Vermont
Washington
Washington, DC
Wisconsin
South Carolina
Illinois
Maine
Massachusetts
Minnesota
New Hampshire
New Jersey
New Mexico
New York
Ohio
Oregon
Pennsylvania
Hawaii
Alaska
Arkansas
California
Colorado
Connecticut
(1) (2) (3) (4)
Sample: All 
Women
Women
 under age 18
Women 
aged 18-30
Women aged 
30 plus
- 0.004 - 0.020 0.003 - 0.004
(0.010) (0.020) (0.008) (0.016)
[0.685] [0.311] [0.702] [0.808]
0.014 0.014 0.022 0.009
(0.008) (0.020) (0.007) (0.013)
[0.100] [0.465] [0.004] [0.512]
Mean of Dep. Var. 6,574.8 269.5 4,257.9 2,047.0
R2 0.999 0.989 0.999 0.998
- 0.001 - 0.001 - 0.002 - 0.016
(0.011) (0.023) (0.012) (0.020)
[0.904] [0.976] [0.882] [0.442]
- 0.006 0.036 - 0.018 0.008
(0.017) (0.022) (0.012) (0.029)
[0.719] [0.102] [0.123] [0.781]
Mean of Dep. Var. 7,012.6 289.6 4,579.3 2,143.3
R2 0.999 0.990 0.999 0.998
A: State Law Changes, 1995-2006
B: FDA Policy Change, 2004-2008
Note: For panel A, N = 7,344 and for panel B N=6,888. Standard errors in 
parentheses are robust to auto-correlation between observations from the same 
state. Related p-values are in brackets.  State fixed effects, month fixed effects, and 
state linear time-trends not shown.  The sample consists of month by state totals of 
all births. The second panel excludes states which changed their legislation such that 
births in 2006-2008 would have been impacted.
Table 2: Effect of EC-Related Laws on Natality
Dependent Variable: The logarithm of births for the given sample
Passed ED-Access 
Law
Passed Pharmacy-
Access Law
No Pharmacy-
Access Law X Post 
FDA
No ED-Access Law 
X Post FDA
(1) (3) (4)
Sample: All 
Ages
Ages
 18-30
Ages 18-30, women 
with High School 
Diploma or less
0.026 0.026 - 0.066
(0.024) (0.026) (0.148)
[0.291] [0.305] [0.660]
- 0.017 - 0.014 - 0.136
(0.051) (0.054) (0.104)
[0.736] [0.797] [0.197]
Mean of Dep. Var. 691.2 504.2 369.3
R2 0.987 0.985 0.984
N 7,344 7,344 5,376
- 0.014 - 0.034 - 0.338
(0.043) (0.045) (0.207)
[0.750] [0.461] [0.111]
0.076 0.086 0.348
(0.059) (0.061) (0.184)
[0.205] [0.169] [0.066]
Mean of Dep. Var. 790.1 580.2 412.4
R2 0.987 0.985 0.984
N 6,888 6,888 4,860
No ED-Access 
Law X Post FDA
No Pharmacy-
Access Law X 
Post FDA
Note: Standard errors in parentheses are robust to auto-correlation between 
observations from the same state. Related p-values are in brackets.  State fixed 
effects, month fixed effects, and state linear time-trends not shown.  The sample 
consists of month by state totals of all births. The second panel excludes states 
which changed their legislation such that births in 2006-2008 would have been 
impacted.
Table 3: Effect of EC-Related Laws on Natality for Black, Unmarried Women
Dependent Variable: The logarithm of births for the given sample
A: State Law Changes, 1995-2006
Passed ED-Access 
Law
Passed Pharmacy-
Access Law
B: FDA Policy Change, 2004-2008
(1) (2) (3) (4)
Sample
All 
Women
Women 
under age 20
Women 
aged 20-29
Women
 aged 30 plus
- 0.052 - 0.074 - 0.043 - 0.071
(0.059) (0.070) (0.083) (0.049)
[0.382] [0.297] [0.605] [0.152]
0.038 - 0.042 - 0.016 - 0.005
(0.075) (0.079) (0.071) (0.049)
[0.615] [0.604] [0.822] [0.917]
Mean of Dep. Var. 16,666.8 3,153.6 9,294.2 4,279.3
R2 0.987 0.972 0.986 0.990
N 505 501 504 503
- 0.128 - 0.115 - 0.027 - 0.020
(0.154) (0.146) (0.111) (0.097)
[0.412] [0.434] [0.811] [0.842]
0.170 0.194 0.056 0.021
(0.135) (0.118) (0.080) (0.060)
[0.217] [0.108] [0.490] [0.729]
Mean of Dep. Var. 10,944.4 2,097.8 6,195.5 2,700.8
R2 0.984 0.960 0.982 0.988
N 403 399 402 401
No Pharmacy-
Access Law X Post 
FDA
Note: Standard errors in parentheses are robust to auto-correlation 
between observations from the same state. Related p-values are in brackets.  
State fixed effects, year fixed effects, and state linear time-trends not shown.  
The sample consists of year by state totals of all abortions, estimated by the 
CDC. The second panel excludes states which changed their legislation 
between 2006 and 2008.
Table 4: Effect of EC-Related Laws on Abortions
Dependent Variable: The logarithm of abortions for the given sample
A: State Law Changes, 1995-2005
Passed ED-Access 
Law
Passed Pharmacy-
Access Law
B: FDA Policy Change, 2004-2008
No ED-Access 
Law X Post FDA
(1) (2) (3) (4)
Dependent Variable: Logarithm of 
Sexual Assaults
Sexual Assaults per 
10,000 People
Logarithm of 
Aggravated Assaults
Aggravated Assaults 
per 10,000 People
0.042 0.215 - 0.061 - 1.638
(0.027) (0.118) (0.038) (1.120)
[0.120] [0.075] [0.112] [0.150]
- 0.093 - 0.308 0.021 - 0.530
(0.036) (0.119) (0.026) (1.219)
[0.013] [0.013] [0.409] [0.666]
Mean of Dep. Var. 1,839.6 3.5 18,411.0 30.0
R2 0.995 0.951 0.997 0.984
0.036 - 0.102 0.038 - 0.121
(0.054) (0.222) (0.032) (1.108)
[0.510] [0.647] [0.243] [0.913]
0.011 0.279 - 0.006 0.190
(0.055) (0.308) (0.046)   
[0.849] [0.371] [0.897] [0.898]
Mean of Dep. Var. 1,797.9 3.5 18,771.6 31.5
R2 0.994 0.941 0.995 0.977
Note: For panel A, N = 561, for panel B, N = 585. Standard errors in parentheses are robust to auto-
correlation between observations from the same state. Related p-values are in brackets.  State fixed effects, 
year fixed effects, and state linear time trends not shown.  The sample consists of year by state totals of all 
assaults reported to the FBI. The second panel excludes states which changed their legislation between 2006 
and 2007.
Table 5: Effect of EC-Related Laws on Reports of Assault
No ED-Access Law 
X Post FDA
No Pharmacy-Access 
Law X Post FDA
Passed ED-Access 
Law
Passed Pharmacy-
Access Law
A: State Law Changes, 1995-2005
B: FDA Policy Change, 2004-2008
(1) (2) (3) (4)
Outcome: Natality Natality Abortion Abortion
Sample: All 
Women
Ages 
18 to 30
All 
Women
Ages
20 to 29
- 0.023 - 0.032 0.024 0.076
(0.020) (0.023) (0.069) (0.051)
[0.268] [0.169] [0.731] [0.146]
- 0.013 - 0.010 0.224 0.071
(0.012) (0.015) (0.159) (0.055)
[0.290] [0.505] [0.164] [0.198]
Mean of Dep. Var. 6,574.8 4,257.9 16,666.8 9,294.2
R2 0.998 0.997 0.965 0.966
N 7,344 7,344 505 504
0.012 0.027 - 0.021 - 0.192
(0.033) (0.031) (0.098) (0.068)
[0.709] [0.375] [0.833] [0.008]
0.022 0.014 - 0.113 0.033
(0.030) (0.031) (0.099) (0.066)
[0.467] [0.657] [0.264] [0.617]
Mean of Dep. Var. 7,012.6 4,579.3 10,944.4 6,195.5
R2 0.998 0.997 0.952 0.954
N 6,888 6,888 403 402
No Pharmacy-
Access Law X Post 
FDA
Note: Standard errors in parentheses are robust to auto-correlation between 
observations from the same state. Related p-values are in brackets.  State fixed 
effects, month fixed effects, and state linear time-trends not shown.  The sample 
consists of month by state totals of all births. The second panel excludes states 
which changed their legislation such that births in 2006-2008 would have been 
impacted.
Appendix Table 1: Effect of EC-Related Laws without Linear Time Trends
Dependent Variable: The logarithm of births or abortions for the given sample
A: State Law Changes, 1995-2006
Passed ED-Access 
Law
Passed Pharmacy-
Access Law
B: FDA Policy Change, 2004-2008
No ED-Access Law 
X Post FDA
(1) (2) (3)
Outcome: Natality Abortion Sexual Assaults
Sample: Ages 
18 to 30
Ages
20 to 29
All 
Women
0.002 - 0.062 0.050
(0.008) (0.095) (0.029)
[0.765] [0.512] [0.089]
0.020 - 0.057 - 0.071
(0.009) (0.098) (0.037)
[0.026] [0.563] [0.059]
0.025 0.029 - 0.117
(0.010) (0.118) (0.060)
[0.021] [0.804] [0.055]
R2 0.999 0.986 0.995
N 7,344 504 561
- 0.007 - 0.049 0.044
(0.011) (0.109) (0.051)
[0.495] [0.652] [0.395]
- 0.031 0.056 0.035
(0.012) (0.080) (0.075)
[0.012] [0.490] [0.640]
0.003 0.101 - 0.021
(0.010) (0.080) (0.041)
[0.765] [0.214] [0.614]
R2 0.999 0.982 0.994
N 6,888 402 585
No ED-Access Law X Post 
FDA
No Pharmacy-Access Law-
Collaborative X Post FDA
Note: Standard errors in parentheses are robust to auto-correlation 
between observations from the same state. Related p-values are in brackets.  
State fixed effects and month fixed effects not shown.  The sample consists 
of month by state totals of all births. The second panel excludes states 
which changed their legislation such that births in 2006-2008 would have 
been impacted.
Passed Pharmacy-Access 
Law-Protocol
No Pharmacy-Access Law-
Protocol X Post FDA
B: FDA Policy Change, 2004-2008
Appendix Table 2: Effect of EC-Related Laws by type
Dependent Variable: The logarithm of births, abortions or 
sexual assault for the given sample
A: State Law Changes, 1995-2006
Passed ED-Access Law
Passed Pharmacy-Access 
Law-Collaborative
